New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C - Episode 2
John Longshore, PhD, FACMG, discusses key molecular markers in metastatic lung cancer.
John Longshore, PhD, FACMG, director, Molecular Pathology, Carolinas Pathology Group, Atrium Health, discusses key molecular markers in metastatic lung cancer.
The National Comprehensive Cancer Network guidelines recommend broad molecular testing. Genes that could harbor potentially actionable mutations and should be tested include EGFR, ALK, ROS1, BRAF, NTRK, HER2, MET exon 14 skipping, RET, and KRAS G12C. Additionally, tumor mutational burden should be profiled, says Longshore.
Despite the wealth of actionable targets in the metastatic setting, EGFR mutations are the only indicated molecular marker for early-stage disease based on the data from the phase 3 ADAURA trial, concludes Longshore.